| 图片： | |
|---|---|
| 名称： | |
| 描述： | |
- B1618乳腺癌类型？084982
图1
图2
图3
图4
图5
| 姓 名： | ××× | 性别： | 女 | 年龄： | 55 |
| 标本名称： | |||||
| 简要病史： | 发现左乳包块半年，细针穿刺乳腺癌，切除送检。 | ||||
| 肉眼检查： | |||||
标签：基底细胞样乳腺癌
相关帖子
×参考诊断
-
本帖最后由 于 2008-11-13 19:35:00 编辑
Agree with 笃行者
Invasive ductal ca with basal-like phenotype:
Triple negative (ER/PR/Her2). Suppose the Her2 is negative based on your report.
In addition to that, you have to have some other markers positive. we general use a panel markers; ck5 (or ck5/6), CK14, CK17, EGFR. Most of the markers will be positive, even though it is not necessary that all of the marker must be positive. In fact CK5 is the most sensitive marker.
abin译：
同意笃行者。
浸润性导管癌伴基底样表型。
三阴（ER/PR/HER2）。根据你的报告假设HER2阴性。
另外，需要其他标记阳性。我们一般使用一组抗体：Ck5（或CK5/6），CK14，CK17，EGFR。大多数为阳性，尽管不需要所有这些标记物全部阳性。实际上CK5是最敏感的标记物。
To Lili0321
Triple negative and basal-like ca are not the same terms. Originally the term of basal-like carcinoma came from the gene profile study. In fact about 80% of triple negative tumors are the basal-like carcinoma. I can show some classic case in future. Basically clinical treatment for these tumor is the same as other invasive ca.
-
stevenshen 离线
- 帖子：343
- 粉蓝豆：2
- 经验：343
- 注册时间：2008-06-03
- 加关注 | 发消息
Would still make the diagnosis of high grade infiltrating ductal carcinoma rather than basal-like carcinoma. May be important in the future, it is not a standard practice to do several immunostains (except ER/PR/Her2) in most hospitals in US unless for research purposes. I do enjoy the discussion about the concept. Thanks.
-
zhoubingjuan 离线
- 帖子：261
- 粉蓝豆：357
- 经验：590
- 注册时间：2007-05-30
- 加关注 | 发消息
-
shn-821128 离线
- 帖子：277
- 粉蓝豆：3
- 经验：277
- 注册时间：2008-11-02
- 加关注 | 发消息
